Education
About Us
Working with TipRanks
Follow Us
Adaptimmune Therapeutics (ADAP)
NASDAQ:ADAP
ADAP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.44 - $1.65
Previous CloseN/A
Volume813.54K
Average Volume (3M)1.49M
Market Cap
$116.45M
Enterprise Value$131.49M
Total Cash (Recent Filing)$143.99M
Total Debt (Recent Filing)$25.23M
Price to Earnings (P/E)―
Beta1.67
Next Earnings
May 15, 2025EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding255,883,210
10 Day Avg. Volume2,402,203
30 Day Avg. Volume1,486,425
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.66
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market Cap1.13
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.61
Enterprise Value/Ebitda-3.45
Forecast
1Y Price Target
$2.13Price Target Upside634.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Adaptimmune Therapeutics News
PremiumCompany Announcements
Adaptimmune’s Earnings Call: TECELRA Success and Future Outlook
PremiumCompany Announcements
Adaptimmune’s Strategic Moves in Cancer Therapy
PremiumCompany Announcements
Adaptimmune Therapeutics Reports Q4 2024 Business Update
PremiumPre-Earnings
Is ADAP a Buy, Before Earnings?PremiumCompany Announcements
Adaptimmune Therapeutics Announces Key Leadership Changes
---
Bulls Say, Bears Say
Bulls Say
Clinical ResultsPositive topline data from lete-cel's pivotal IGNYTE-ESO study supports ADAP’s plans for a rolling BLA submission.
Market AdoptionTecelra's FDA approval and smooth adoption process at MSK lay a solid foundation for lete-cel’s future market adoption.
Therapy PotentialLete-cel demonstrated an overall response rate of 42% for sarcoma patients, significantly higher than current therapies achieving only 4-7%.
Bears Say
Financial PerformanceZero sales were reported for the Tecelra launch, and no meaningful revenue is expected shortly.
Program DiscontinuationThe discontinuation of enrollment in the SURPASS-3 study due to a reallocation of resources means the full dataset anticipated in 2026 will no longer be available.
Strategic ChangesA 33% workforce reduction was announced as a necessary measure to help the company achieve break-even.
---
Ownership Overview
48.53% Insiders
0.10% Mutual Funds
0.01% Other Institutional Investors
51.10% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ADAP FAQ
What was Adaptimmune Therapeutics’s price range in the past 12 months?
Adaptimmune Therapeutics lowest stock price was $0.43 and its highest was $1.65 in the past 12 months.
What is Adaptimmune Therapeutics’s market cap?
Adaptimmune Therapeutics’s market cap is $116.45M.
When is Adaptimmune Therapeutics’s upcoming earnings report date?
Adaptimmune Therapeutics’s upcoming earnings report date is May 15, 2025 which is in 53 days.
How were Adaptimmune Therapeutics’s earnings last quarter?
Adaptimmune Therapeutics released its earnings results on Mar 20, 2025. The company reported -$0.035 earnings per share for the quarter, missing the consensus estimate of -$0.03 by -$0.005.
Is Adaptimmune Therapeutics overvalued?
According to Wall Street analysts Adaptimmune Therapeutics’s price is currently Undervalued.
Does Adaptimmune Therapeutics pay dividends?
Adaptimmune Therapeutics does not currently pay dividends.
What is Adaptimmune Therapeutics’s EPS estimate?
Adaptimmune Therapeutics’s EPS estimate is -0.13.
How many shares outstanding does Adaptimmune Therapeutics have?
Adaptimmune Therapeutics has 255,883,210 shares outstanding.
What happened to Adaptimmune Therapeutics’s price movement after its last earnings report?
Adaptimmune Therapeutics reported an EPS of -$0.035 in its last earnings report, missing expectations of -$0.03. Following the earnings report the stock price went down -37.778%.
Which hedge fund is a major shareholder of Adaptimmune Therapeutics?
Currently, no hedge funds are holding shares in ADAP
---
Adaptimmune Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$2.13 (634.48% Upside)
$2.13 (634.48% Upside)
Blogger Sentiment
Bullish
ADAP Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 37.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.2%
Last 30 Days ▼ 10.1%
Last 30 Days ▼ 10.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-78.94%
12-Months-Change
Fundamentals
Return on Equity
-53.54%
Trailing 12-Months
Asset Growth
7.01%
Trailing 12-Months
Company Description
Adaptimmune Therapeutics
Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.
---
ADAP Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlights substantial progress in the TECELRA launch, strong manufacturing and reimbursement success, and promising developments for future products like Lete-cel. However, the company faces challenges in securing additional capital to reach profitability by 2027 and delayed financial reporting. Overall, the positive aspects, particularly in product launch and efficiency, outweigh the financial and capital concerns.Read More>---
ADAP Stock 12 Month Forecast
Average Price Target
$2.13
▲(634.48% Upside)
Technical Analysis
Gilead Sciences
―
Bluebird Bio
―
Fate Therapeutics
―
Iovance Biotherapeutics
―
Immatics
―
Best Analysts Covering ADAP
1 Year
1 Year Success Rate
8/11 ratings generated profit
1 Year Average Return
+33.33%
reiterated a sell rating 4 months ago
Copying Peter Lawson's trades and holding each position for 1 Year would result in 72.73% of your transactions generating a profit, with an average return of +33.33% per trade.
---